Oculis Holding AG - Ordinary shares (OCS)

In our clinic, evaluating the PIONEER-1 trial parameters requires close attention to the FDA Special Protocol Assessment endpoint—specifically the proportion of patients gaining 15 or more letters in low-contrast visual acuity at Month 3. When prepping clinical teams or interviewing external advisors on Privosegtor's potential in acute MS relapses, make sure they understand how the pre-IND feedback shapes this registrational pathway. The pivot to neuro-ophthalmology is entirely dependent on mastering these exact visual function metrics.

Hedging with Q4 put spreads makes a lot of sense here given the binary nature of the upcoming PREDICT-1 topline data around year-end. With the trial now >45% randomized and all sites live, the clock is ticking visibly. At the same time, the $61.3M in quiet ATM issuance pushed cash up to $282.3 million, giving management a comfortable runway into 2H 2029. Balance sheet dilution is real, but solvency risk is largely off the table for the next three years.

On our desk, we are watching the market's psychological recovery following the >35% plunge from the Phase 3 DIAMOND trial setbacks. Sentiment on StockTwits and Twitter is deeply polarized between bruised retail holders and bulls focusing on the new management narrative. The outright buyout of Accure's rights to Privosegtor for $3.8M cash plus up to 2.05M shares is seen internally as a bold stroke to clear out legacy structural liabilities, but the market wants to see clean execution on PREDICT-1 before trusting the valuation again.

As a bio-analyst reviewing the licaminlimab program in dry eye disease, my technical protocol focus is squarely on patient enrollment velocity. Management confirmed during the Q2 2026 update that all planned sites are activated and over 45% of patients are randomized. Interviewing trial investigators reveals that site engagement is currently high, but maintaining retention through the final stretch before the year-end readout will dictate whether the data meets primary endpoints.

From a hedge fund PM perspective, sell-side enthusiasm remains resilient despite the clinical setbacks. LifeSci Capital maintaining its $45 price target and H.C. Wainwright holding a $26 target—both with Buy ratings—provide a firm institutional floor. However, retail sentiment remains cautious with a prevailing 'Hold' consensus until concrete data catalysts materialize. We are sizing our positions carefully to avoid getting chopped up by short-term sentiment shifts.